BR112017023147A2 - azabenzimidazóis e seu uso como moduladores do receptor de ampa - Google Patents

azabenzimidazóis e seu uso como moduladores do receptor de ampa

Info

Publication number
BR112017023147A2
BR112017023147A2 BR112017023147-6A BR112017023147A BR112017023147A2 BR 112017023147 A2 BR112017023147 A2 BR 112017023147A2 BR 112017023147 A BR112017023147 A BR 112017023147A BR 112017023147 A2 BR112017023147 A2 BR 112017023147A2
Authority
BR
Brazil
Prior art keywords
azabenzimidazoles
ampule
receptor modulators
compounds
formula
Prior art date
Application number
BR112017023147-6A
Other languages
English (en)
Inventor
G.B. Berry Cynthia
Chen Gang
Loic Jourdan Fabrice
Patrick Lebold Terry
Wei LIN David
Angel Pena Piñón Miguel
Ravula Suchitra
M. SAVALL Bradley
M. Swanson Devin
Wu Dongpei
Zhang Wei
K. Ameriks Michael
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority to BR122023023802-8A priority Critical patent/BR122023023802A2/pt
Publication of BR112017023147A2 publication Critical patent/BR112017023147A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

são aqui fornecidos compostos de fórmula (i) e sais, n-óxidos ou solvatos farmaceuticamente aceitáveis dos mesmos, (i) também são aqui fornecidas composições farmacêuticas que compreendem os compostos de fórmula (i) e métodos de uso dos compostos de fórmula (i).
BR112017023147-6A 2015-04-29 2016-04-28 azabenzimidazóis e seu uso como moduladores do receptor de ampa BR112017023147A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023023802-8A BR122023023802A2 (pt) 2015-04-29 2016-04-28 Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
US62/154,313 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
BR112017023147A2 true BR112017023147A2 (pt) 2018-07-10

Family

ID=56008859

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122023023802-8A BR122023023802A2 (pt) 2015-04-29 2016-04-28 Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem
BR112017023147-6A BR112017023147A2 (pt) 2015-04-29 2016-04-28 azabenzimidazóis e seu uso como moduladores do receptor de ampa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122023023802-8A BR122023023802A2 (pt) 2015-04-29 2016-04-28 Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem

Country Status (39)

Country Link
US (4) US11312712B2 (pt)
EP (3) EP3288940B9 (pt)
JP (2) JP6800886B2 (pt)
KR (2) KR20170140382A (pt)
CN (1) CN107835814B (pt)
AR (1) AR104447A1 (pt)
AU (2) AU2016255434C1 (pt)
BR (2) BR122023023802A2 (pt)
CA (1) CA2983826A1 (pt)
CO (1) CO2017011017A2 (pt)
CR (1) CR20170484A (pt)
CY (1) CY1124059T1 (pt)
DK (1) DK3288940T5 (pt)
EA (1) EA033281B1 (pt)
EC (1) ECSP17074645A (pt)
ES (1) ES2865330T3 (pt)
GT (1) GT201700231A (pt)
HK (1) HK1252249A1 (pt)
HR (1) HRP20210403T1 (pt)
HU (1) HUE053943T2 (pt)
IL (1) IL254848B (pt)
JO (1) JO3654B1 (pt)
LT (1) LT3288940T (pt)
MA (1) MA41988B1 (pt)
MD (1) MD3288940T2 (pt)
MX (1) MX2017013886A (pt)
MY (1) MY194104A (pt)
NI (1) NI201700129A (pt)
PH (1) PH12017501816A1 (pt)
PL (1) PL3288940T3 (pt)
PT (1) PT3288940T (pt)
RS (1) RS61688B1 (pt)
SG (1) SG11201708190UA (pt)
SI (1) SI3288940T1 (pt)
TW (1) TWI706952B (pt)
UA (1) UA120304C2 (pt)
UY (1) UY36654A (pt)
WO (1) WO2016176460A1 (pt)
ZA (1) ZA201708065B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107567452B (zh) * 2015-04-29 2020-07-07 詹森药业有限公司 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
JP7250687B2 (ja) * 2017-10-06 2023-04-03 武田薬品工業株式会社 複素環化合物
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
MX2021005012A (es) * 2018-10-30 2021-07-21 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (pt) * 1992-11-02 1995-07-11 Pfizer
NZ276172A (en) 1994-02-10 1998-02-26 Pfizer 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists, 5-(hetero)arylaminoindole intermediates
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
MXPA01006742A (es) 1998-12-31 2004-04-21 Sugen Inc Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
US20030225127A1 (en) 2000-08-11 2003-12-04 Bender David Michael Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PL1786812T3 (pl) * 2004-09-03 2012-04-30 Merck Serono Sa Pirydynometylenoazolidynony i ich zastosowanie jako inhibitorów fosfoinozytydów
EA016286B1 (ru) 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
ATE502675T1 (de) 2006-11-03 2011-04-15 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
WO2009073777A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
WO2011156245A2 (en) * 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
GEP20156216B (en) 2010-08-10 2015-01-12 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2013064984A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
CN105121439A (zh) * 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物

Also Published As

Publication number Publication date
CN107835814B (zh) 2021-07-23
AU2016255434B2 (en) 2020-05-14
CY1124059T1 (el) 2022-05-27
US20210284641A1 (en) 2021-09-16
EP3288940B1 (en) 2021-02-24
JP2018518462A (ja) 2018-07-12
KR20240017991A (ko) 2024-02-08
AU2020210231A1 (en) 2020-08-20
NI201700129A (es) 2019-05-10
DK3288940T5 (da) 2021-09-20
BR122023023802A2 (pt) 2023-12-26
TWI706952B (zh) 2020-10-11
HRP20210403T1 (hr) 2021-10-29
CO2017011017A2 (es) 2018-03-20
JO3654B1 (ar) 2020-08-27
IL254848A0 (en) 2017-12-31
GT201700231A (es) 2018-12-20
MA41988B1 (fr) 2021-03-31
UY36654A (es) 2016-10-31
EA033281B1 (ru) 2019-09-30
AU2020210231B2 (en) 2021-07-22
SG11201708190UA (en) 2017-11-29
PH12017501816A1 (en) 2018-04-23
JP7026194B2 (ja) 2022-02-25
ECSP17074645A (es) 2018-02-28
EP3901153A1 (en) 2021-10-27
MD3288940T2 (ro) 2021-08-31
PT3288940T (pt) 2021-04-30
EP3288940A1 (en) 2018-03-07
SI3288940T1 (sl) 2021-07-30
AU2016255434A1 (en) 2017-10-26
MA41988A (fr) 2018-07-03
UA120304C2 (uk) 2019-11-11
JP2021042230A (ja) 2021-03-18
US20180118740A1 (en) 2018-05-03
KR20170140382A (ko) 2017-12-20
AR104447A1 (es) 2017-07-19
RS61688B1 (sr) 2021-05-31
HUE053943T2 (hu) 2021-08-30
CA2983826A1 (en) 2016-11-03
US20230110576A1 (en) 2023-04-13
CN107835814A (zh) 2018-03-23
TW201708217A (zh) 2017-03-01
NZ736057A (en) 2023-08-25
WO2016176460A1 (en) 2016-11-03
ZA201708065B (en) 2019-09-25
MY194104A (en) 2022-11-11
CR20170484A (es) 2018-02-26
LT3288940T (lt) 2021-05-10
US11312712B2 (en) 2022-04-26
ES2865330T3 (es) 2021-10-15
AU2016255434C1 (en) 2021-09-23
EP4144736A1 (en) 2023-03-08
EP3288940B9 (en) 2021-07-21
EA201792374A1 (ru) 2018-05-31
HK1252249A1 (zh) 2019-05-24
JP6800886B2 (ja) 2020-12-16
US20230114165A1 (en) 2023-04-13
MX2017013886A (es) 2018-03-12
IL254848B (en) 2021-01-31
PL3288940T3 (pl) 2021-07-12
DK3288940T3 (da) 2021-05-25

Similar Documents

Publication Publication Date Title
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
BR112016008849B8 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112017023080A2 (pt) compostos benzimidazolona e benzotiazolona e uso dos mesmos como moduladores do receptor de ampa
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
TR201900659T4 (tr) Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
BR112017023200A2 (pt) compostos de indolona e seu uso como moduladores do receptor de ampa
BR112019008606A2 (pt) inibidores de interações de mtor-deptor e métodos de uso dos mesmos
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023023802-8 PROTOCOLO 870230100282 EM 13/11/2023 17:36.

B25A Requested transfer of rights approved

Owner name: PRECISION NEUROSCIENCE NEWCO, INC. (US)

B25D Requested change of name of applicant approved

Owner name: RAPPORT THERAPEUTICS, INC. (US)

B25G Requested change of headquarter approved

Owner name: RAPPORT THERAPEUTICS, INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]